Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

Introduction: The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and NSCLC. Whether this association exists in patients with SCLC is currently unknown. Methods: We conducted...

Full description

Bibliographic Details
Main Authors: Biagio Ricciuti, MD, Abdul Rafeh Naqash, MD, Jarushka Naidoo, MD, Kartik Sehgal, MD, Adam Miller, MD, Kenneth Kehl, MD, MPH, Deepti Venkatraman, MPH, Jacob Sands, MD, Giuseppe Lamberti, MD, Gonzalo Recondo, MD, PhD, Jiajia Zhang, MD, Shravanti Macherla, MD, Sameer Baig, MD, Paul Walker, MD, Deepa Rangachari, MD, Justin F. Gainor, MD, Daniel B. Costa, MD, Naiyer Rizvi, MD, Lynette M. Sholl, MD, Mizuki Nishino, MD, MPH, Brian Henick, MD, Anna F. Farago, MD, PhD, Mark M. Awad, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:JTO Clinical and Research Reports
Subjects:
SCLC
irAEs
PD-(L)1
CTLA-4
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320300977

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320300977

Similar Items